<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927808</url>
  </required_header>
  <id_info>
    <org_study_id>22904/25.5.2016</org_study_id>
    <nct_id>NCT02927808</nct_id>
  </id_info>
  <brief_title>Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy Compliance in Patients With Acute Coronary Syndromes: a Prospective Randomized Clinical Study</brief_title>
  <acronym>IDEAL-LDL</acronym>
  <official_title>Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy Compliance in Patients With Acute Coronary Syndromes: a Prospective Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the impact of motivational interviewing in achieving low-density&#xD;
      lipoprotein cholesterol therapeutic targets in patients with acute coronary syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether a strategy of enhanced information about the risks of high plasma&#xD;
      low-density lipoprotein cholesterol (LDL-C) and the importance of lipid-lowering medication&#xD;
      together with close follow-up and motivational interviewing is superior than usual care in&#xD;
      achieving LDL-C therapeutic targets, as set by current practice guidelines (LDL-C &lt;70 mg/dL&#xD;
      or &gt;50% reduction from baseline LDL-C) in patients with acute coronary syndromes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of low-density lipoprotein cholesterol therapeutic goal, as specified by current practice guidelines (LDL-C &lt;70 mg/dL or &gt;50% reduction from baseline LDL-C)</measure>
    <time_frame>12 months after discharge from hospital</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall adherence to lipid-lowering regimen, reported as both a continuous and a binary outcome, by using the 4-item Morisky Medication-Taking Adherence Scale</measure>
    <time_frame>12 months after discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention group - Motivational Interview</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the intervention group will be given a leaflet entitled &quot;Information leaflet about LDL Cholesterol&quot; that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interview</intervention_name>
    <description>Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.</description>
    <arm_group_label>Intervention group - Motivational Interview</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject hospitalized for acute coronary syndrome (STEMI, NTEMI or unstable angina)&#xD;
&#xD;
          -  Subject currently on lipid-lowering therapy or prescribed lipid-lowering therapy at&#xD;
             hospital discharge (statins and/or other agents)&#xD;
&#xD;
          -  Subject who is 18 years or older&#xD;
&#xD;
          -  Subject or legally authorized representative who is willing and capable of providing&#xD;
             informed consent, participating in all associated study activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject unable to communicate via telephone for study interviewing&#xD;
&#xD;
          -  Subject with contraindication to statin therapy&#xD;
&#xD;
          -  Subject with any medical disorder that would interfere with completion or evaluation&#xD;
             of clinical study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Leonidas Lillis</investigator_full_name>
    <investigator_title>MD, Clinical Research Associate</investigator_title>
  </responsible_party>
  <keyword>Motivational Interviewing</keyword>
  <keyword>LDL-C</keyword>
  <keyword>LDL target</keyword>
  <keyword>Medication adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

